Education
About Us
Working with TipRanks
Follow Us
Harrow Health (HROW)
:HROW
HROW Stock Chart & Stats
Day’s Range― - ―
52-Week Range$20.85 - $59.23
Previous CloseN/A
Volume51.77K
Average Volume (3M)815.48K
Market Cap
$1.39B
Enterprise Value$1.36B
Total Cash (Recent Filing)$52.96M
Total Debt (Recent Filing)$231.25M
Price to Earnings (P/E)―
Beta1.98
Next Earnings
Nov 17, 2025EPS Estimate
0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.13
Shares Outstanding37,002,136
10 Day Avg. Volume1,150,761
30 Day Avg. Volume815,475
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue5.99
Enterprise Value/Gross Profit8.04
Enterprise Value/Ebitda42.50
Forecast
1Y Price Target
$68.50Price Target Upside76.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Bulls Say, Bears Say
Bulls Say
Market PositionHarrow is advancing its position as a leader in the U.S. ophthalmic pharmaceutical market with the growth of its FDA-approved franchise.
Product LaunchesThe relaunch of TRIESENCE is anticipated with broad applications beyond its current use, suggesting significant future potential.
Strategic InitiativesThe company's recent debt refinancing cleans up the balance sheet, lowers interest expenses, and adds incremental liquidity to support additional business development transactions.
Bears Say
Debt ExpensesThe refinancing deal will likely bring forward some debt extinguishment expenses into the third quarter, potentially affecting estimates.
SeasonalityThe seasonality in the company’s underlying business could drive some volatility in the stock.
Harrow Health News
HROW FAQ
What was Harrow Health’s price range in the past 12 months?
Harrow Health lowest stock price was $20.85 and its highest was $59.23 in the past 12 months.
What is Harrow Health’s market cap?
Harrow Health’s market cap is $1.39B.
When is Harrow Health’s upcoming earnings report date?
Harrow Health’s upcoming earnings report date is Nov 17, 2025 which is in 33 days.
How were Harrow Health’s earnings last quarter?
Harrow Health released its earnings results on Aug 11, 2025. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.008 by $0.122.
Is Harrow Health overvalued?
According to Wall Street analysts Harrow Health’s price is currently Undervalued.
Does Harrow Health pay dividends?
Harrow Health does not currently pay dividends.
What is Harrow Health’s EPS estimate?
Harrow Health’s EPS estimate is 0.22.
How many shares outstanding does Harrow Health have?
Harrow Health has 37,002,136 shares outstanding.
What happened to Harrow Health’s price movement after its last earnings report?
Harrow Health reported an EPS of $0.13 in its last earnings report, beating expectations of $0.008. Following the earnings report the stock price went up 3.231%.
Which hedge fund is a major shareholder of Harrow Health?
Currently, no hedge funds are holding shares in HROW
Harrow Health Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$68.50 (76.68% Upside)
$68.50 (76.68% Upside)
Blogger Sentiment
Bullish
HROW Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 272.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.1%
Last 30 Days ▲ 24.7%
Last 30 Days ▲ 24.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-23.54%
12-Months-Change
Fundamentals
Return on Equity
-18.99%
Trailing 12-Months
Asset Growth
12.69%
Trailing 12-Months
Company Description
Harrow Health
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
HROW Company Deck
HROW Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call conveyed strong growth and strategic developments with significant revenue increases and strategic alliances. However, there were challenges with the VEVYE revenue decline and underperformance in the specialty branded portfolio.View all HROW earnings summariesHROW Stock 12 Month Forecast
Average Price Target
$68.50
▲(76.68% Upside)
Technical Analysis
Avadel Pharmaceuticals
―
Pacira Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Evotec AG
―
Ownership Overview
26.47% Insiders
9.69% Mutual Funds
24.59% Other Institutional Investors
28.42% Public Companies and Individual Investors